Vertex Pharmaceuticals Inc. closed $47.49 short of its 52-week high ($510.64), which the company reached on August 1st.

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.65% higher to $462.99 Tuesday, on what proved to be an all-around great ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...

The average brokerage recommendation (ABR) for Vertex (VRTX) is equivalent to a Buy. The overly optimistic recommendations of ...

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $462.99 which represents a slight increase of $2.99 or 0.65% from the prior close of $460. The stock opened at ...

Vertex Pharmaceuticals Inc. (VRTX) said that Health Canada has granted Marketing Authorization for CASGEVY (exagamglogene ...

Discover Vertex Pharmaceuticals' groundbreaking patent for variant PD-1 polypeptides, enhancing immunomodulatory proteins for innovative cancer and immune therapies.